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Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder which can affect multiple
organs of the body, requiring ongoing disease management and healthcare resource utilization. The economic
impact of SLE has not been evaluated in a Medicare population to date. This study was conducted to assess the
prevalence of SLE and its burden in terms of healthcare resource utilization and costs in a US Medicare population.
Methods: This was a retrospective observational study using Medicare medical claims data (5% random sample) for
the period spanning 2003 to 2007. SLE patients were identified by having ≥2 medical claims with a primary or
secondary diagnosis of ICD-9 code 710.0X. The earliest quarter of SLE diagnosis was defined as the index quarter.
Prevalence of SLE, the proportion of SLE cases on disability benefits, and the contribution of SLE to new disability
cases were evaluated. Healthcare resource utilization and direct medical costs (2008 US dollars) over 12 months
were compared between a cohort of patients with SLE and a cohort without SLE matched on key demographics.
Differences in outcomes between cohorts were assessed using McNemar’s test for dichotomous variables and
paired t-tests for continuous variables.
Results: A total of 13,348 patients with SLE were identified. The prevalence of SLE was approximately 3 per 1000
Medicare beneficiaries. After matching, the sample consisted of 6,707 SLE and 13,414 non-SLE patients. On average, the
SLE cohort compared with the non-SLE cohort had 2.4 times more physician visits, 2.7 times more hospitalizations, 2.2
times more outpatient visits, and 2.1 times more emergency room visits. A medical cost surplus of approximately $10,229
per patient per year in the SLE cohort relative to the non-SLE cohort was driven largely by inpatient hospitalization costs
(p < 0.001).
Conclusions: SLE prevalence was 3 per 1,000 Medicare patients. Patients with SLE consumed significantly more health
care resources with significantly greater costs compared with those without SLE. Added costs were largely attributable to
inpatient hospitalizations. The Medicare population is an important target for efforts to improve SLE disease management
and reduce costs.
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Systemic lupus erythematosus (SLE) is a chronic auto-
immune inflammatory disorder that causes significant
morbidity and mortality [1]. SLE has an estimated inci-
dence of 5 per 100,000 persons and a prevalence of 100
per 100,000 persons in the United States [2-5]. A
relapsing-remitting condition in which periods of mild
disease activity alternate with flares of increased disease
activity, SLE is manifested mainly in women, but also in
children and men, with clinical and pathologic manifes-
tations involving almost all bodily organs [1,6,7]. Symp-
toms can include fatigue, joint pain and sensitivity,
malar rash on the face, and skin photosensitivity. Com-
plications can include kidney damage, including kidney
failure, cognitive and memory impairment, neuropsychi-
atric symptoms, blood disorders and cardiovascular dis-
ease [8-10]. Although SLE is currently incurable,
survival rates and longevity have increased in recent de-
cades with improvements in diagnosis and therapy
[1,5,11]. Management of SLE focuses on reducing dis-
ease activity and preventing or reducing disease flares
[7], which impair quality of life and cause disability with
associated reductions in productivity and loss of employ-
ment [12-20].
The economic impact of SLE has been evaluated in
managed care or Medicaid populations [21-25], but not
assessed to date in a Medicare population. In 2010,
Medicare provided healthcare coverage for approxi-
mately 47.5 million Americans (39.6 million ages 65 and
older, and 7.9 million disabled) and enrollment is pro-
jected to reach 78 million by 2030 [26]. Generally, indi-
viduals ages 65 years and older who have a ≥5-year
status as legal residents of the United States are eligible
for Medicare as are disabled people younger than 65
years who receive Social Security Disability Insurance
benefits and people who receive dialysis for end-stage
renal disease or need a kidney transplant [26]. The in-
creasing longevity of patients with SLE [1,5,11], frequent
renal involvement including the need for dialysis and
kidney transplant [27-29], and the association of SLE
with disability [14,15,18,19], potentially make Medicare a
major source of healthcare coverage for SLE patients
and could render the cost of SLE in the Medicare popu-
lation substantial. The present study was conducted to
assess the prevalence of SLE and its burden in terms of
healthcare resource utilization and costs in a US
Medicare population, for both the overall Medicare
population and for those patients <65 years of age re-
ceiving disability benefits through Medicare.
Methods
This retrospective analysis (GHO-09-1623) assessed the
prevalence of SLE, the proportion of SLE cases on dis-
ability benefits, the contribution of SLE to new disabilitycases each year, and healthcare resource utilization and
costs in a Medicare population from 2003–2007.
Database and sample
This analysis was conducted using a 5% random sample
of Medicare’s medical claims database obtained from the
Centers for Medicare and Medicaid Services (CMS).
This database is a nationally representative sample of pa-
tients seeking medical care through Medicare providers
and can be extrapolated to the entire Medicare popula-
tion. It contains all inpatient fee-for-service claims (Part
A) and outpatient fee-for-service claims (Part B) for
beneficiaries. Prescription data (Part D) was not available
for this study. Actual dates of service are not available in
the database, therefore the quarter in which the service
was rendered is utilized.
Inclusion criteria for the target SLE cohort were pa-
tients having 2 or more medical claims with a primary
or secondary diagnosis of SLE (International Classifica-
tion of Diseases, 9th edition (ICD-9) code 710.0x) during
the identification period (first quarter of 2003 through
the fourth quarter of 2006). The index quarter was de-
fined as the earliest quarter of SLE diagnosis for the SLE
cohort. For the non-SLE control group, inclusion criteria
required that patients never had SLE during the study
period. The index quarter for non-SLE patients was de-
fined as the first quarter of Medicare enrollment for pa-
tients 65 years and older or the first quarter with a
qualifying disability for patients under the age of 65
years. Patients were excluded from the non-SLE control
group if they were <65 years of age with end stage renal
disease (ESRD). Patient-level data were de-identified and
thus exempt from institutional board review and ethics
committee approval. The study was conducted in ac-
cordance with the principles of the Health Insurance
Portability and Accountability Act (HIPAA).
Prevalence of SLE
The prevalence of SLE during each study year 2003–
2007 was calculated as the number of SLE cases in a
given calendar year divided by the number of Medicare
beneficiaries who were continuously eligible during the
same calendar year. The date of the first SLE claim was
used in the prevalence calculations.
SLE patients receiving disability benefits
The proportion of patients with SLE receiving disability
benefits in a given year from 2003–2007 was calculated
as the number of SLE cases with qualifying disability di-
vided by the total number of SLE cases. Medicare bene-
ficiaries (including SLE patients) were deemed to receive
disability based on the entitlement code (value of 1=’dis-
ability insurance benefits’ or 3=’disability insurance ben-
efits and ESRD’) listed on claims. The proportion of new
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number of new SLE cases with qualifying disability in a
given year from 2003–2007 divided by the number of
new disability cases in that year. The date of the first
SLE claim was used in the disability analyses.
Healthcare resource utilization and costs
Healthcare resource utilization and healthcare costs
were compared between cohorts with and without SLE
matched 1:2 on the basis of age (±2 years), gender, race,
region, and index quarter (±2). To be eligible for the
matched sample, patients had to have a first SLE diagno-
sis that occurred from the first quarter of 2003 through
the fourth quarter of 2006 (index quarter) and had to be
continuously eligible for medical services during the 2
quarters before and the 1 year after the index quarter.
Outcomes were evaluated for 1 year after the index
quarter and included all-cause healthcare utilization
and costs (inflated to 2008 US dollars) for inpatient
hospitalizations, emergency room visits, physician visits,
and outpatient visits. Outpatient drug costs were not deter-
mined because these records are not included in the Medi-
care Part A or Part B datasets. Healthcare utilization and
costs were summarized both for the matched sample as a
whole and for the subset of the matched sample on disabil-
ity benefits. Healthcare costs were also summarized in the
matched sample as a whole as a function of race and gen-
der. Re-hospitalization rates and average length of stay were
also calculated.
Statistical analysis
Inferential statistics was used to describe and quantify
inter-cohort differences in baseline characteristics before
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Figure 1 Prevalence of SLE in a Medicare population: 2003–2007.characteristics were compared between cohorts using
paired t-tests or Wilcoxon signed rank tests (continuous
variables) and McNemar’s test (categorical variables).
SLE prevalence, the proportion of SLE cases on disability
benefits, and the contribution of SLE to new disability
cases were summarized with descriptive statistics. Out-
comes were compared statistically between cohorts
using paired t-tests for continuous variables and McNe-
mar’s test for categorical variables. Outcome compari-
sons were conducted for the sample as a whole and
stratified by race and gender. Differences between co-
horts were considered statistically significant at p <
0.001. SAS software was used for statistical analysis (©
SAS Institute Inc, Cary, NC).
Results
Prevalence of SLE
The number of Medicare beneficiaries for the study
period (5% random sample) was 2,719,310 of whom
13,348 had 2 or more claims for SLE. The prevalence of
SLE in the overall Medicare population from 2003–2007
(Figure 1) remained relatively stable at approximately 3
per 1000 Medicare beneficiaries (range 3.07-3.30). The
SLE prevalence among Medicare beneficiaries < 65 years
of age receiving disability was approximately 10 per
1000, while the prevalence for the ≥ 65 Medicare popula-
tion was approximately 2 per 1000.
SLE patients receiving disability benefits
The number of new disability cases per year in the 5%
random sample of the Medicare claims database
remained relatively stable (range 35,597-37,704) from
2003–2007. The proportion of new disability cases at-





65 years of age ≥ 65 years of age
Table 2 Patient characteristics post-matching
Characteristic SLE cohort Non-SLE cohort-matched controls
N = 6707 N = 13,414
Disability benefits, % 49.9 49.9
Mean age, years 61 61
















No significant differences between groups.
Table 1 Patient characteristics pre-matching
Medicare disabled age
<65 years









N = 5,555 N = 455,950 N = 7,793 N = 2,250,012
Mean age,
years
49 50 74 74
Female, % 87* 46* 83** 57**
Race, %
White 62.6* 73.3* 84.3 85.5
Black 28.3* 18.4* 10.1 8.2
Other 9.2 8.3 4.4 6.3
Region, %
Northeast 15.9* 18.4* 19.2 19.9
Midwest 18.9* 21.4* 19.7** 23.0**
South 46.3* 39.9* 42.3** 35.0**
West 16.8* 17.6* 17.7** 20.1**
Other 2.1 2.8 1.2 2.1
*P < 0.05 between Medicare Disabled age <65 cohorts.
**P < 0.05 between Medicare age ≥65 cohorts.
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ability benefits increased from 45.0% in 2003 to 49.7% in
2007.
Patient sample and demographics
A total of 13,348 patients met criteria for inclusion in
the SLE cohort and 2,705,962 patients met criteria for
the non-SLE cohort. Patient characteristics prior to
matching are shown in Table 1. Matching identified a
match for half of the SLE cohort (N = 6,707). These pa-
tients were matched 1:2 to 13,414 control patients with-
out SLE. Patient characteristics were similar across the
matched cohorts (Table 2). Mean age was 61 years and
86% were female. Half of the patients in each cohort
were receiving disability benefits.
Healthcare utilization
In the matched sample overall, the percentage of pa-
tients in the SLE cohort who utilized all categories of
healthcare, including physician visits, in-patient visits,
outpatient visits, and emergency room visits, was signifi-
cantly larger than the percentage utilized by the non-
SLE cohort (Figure 2). The biggest difference was seen
in hospitalizations (40.2% in SLE cohort vs. 17.2% in the
non-SLE cohort, p < 0.001). Likewise, the average annual
number of uses of each of these categories of healthcare
was significantly higher in the SLE cohort than the non-
SLE cohort (Figure 3). The same pattern of significant
differences in utilization (proportion of patients and
average number of visits) between the SLE and non-SLE
cohorts was observed in the subset of the matched sam-
ple on disability benefits (Figures 2, 3), and when the
total sample was stratified by race and gender (data not
shown).
In post-hoc analyses of patients with at least one
hospitalization, the average length of hospital stay was
6.4 days for both the SLE and non-SLE cohorts. Re-
hospitalization rates were numerically higher (not tested
for significance) in the SLE cohort (53%) compared with
the non-SLE cohort (43%).
Healthcare costs
Patients with SLE incurred significantly greater average an-
nual healthcare costs than matched controls without SLE
(Figure 4). The cost surplus of approximately $10,330 (2008
US dollars) in the SLE cohort relative to the non-SLE co-
hort was driven primarily by inpatient hospital costs, which
were approximately 2.7 times greater in patients with SLE.
Costs for other categories of healthcare use, including out-
patient visits, physician visits, and emergency room visits
were at least 2 times greater in the SLE cohort compared
with the non-SLE cohort. The same pattern of significant
differences in cost between the SLE and non-SLE cohorts
was observed in the subset of the matched sample ondisability benefits, and when the total sample was stratified
by race and gender (Figure 4). The magnitude of the differ-
ence in healthcare costs between the SLE cohort and the
non-SLE cohort was greater for blacks than for whites, but
was similar between males and females.










































Figure 2 Annual Healthcare Resource Utilization – proportion of patients. *p < 0.0001 versus non-SLE group. MD = physician visits; IP = inpatient
visits; OP = outpatient visits; ER = emergency room visits.
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Although several cost of illness studies have been con-
ducted in patients with SLE in managed care or Medicaid
populations, this is the first study to evaluate the preva-
lence, healthcare resource utilization and cost of SLE in a
sample of Medicare beneficiaries. The prevalence of SLE in
this large US Medicare population was found to be ap-
proximately 3 per 1000 across the 5-year study period span-
ning 2003 to 2007. This prevalence rate exceeds the
approximate 1 per 1000 persons estimate obtained from
several studies conducted in various settings during the past
3 decades [2-5]. The higher prevalence of SLE overall in
this Medicare sample is driven by the increased prevalence
of SLE in the disabled cohort (approximately 10 per 1000)
compared with the SLE patients >65 years of age (approxi-
mately 2 per 1000).
The findings that approximately half of SLE patients in
this study were on disability benefits and that approxi-
mately 2% of new disability cases were attributed to SLE
are consistent with previous reports linking SLE to func-
tional impairment, poor quality of life, reduced product-
ivity, and unemployment [12-20]. In a review of 12
studies (including patients from US and Europe) on em-
































Figure 3 Annual Healthcare Resource Utilization – average number of visit
sample and disability subset.inability to work or cessation of work ranged from 15%
to 51% across studies and 20% to 32% of SLE patients
received disability benefits [14]. While our analysis
found that approximately half of SLE patients received
disability benefits under Medicare, the large variance in
percentage of patients receiving disability benefits in the
review paper is likely attributable to the sources of data
and differing definitions of disability benefits since pa-
tients from countries other than the US were included.
Patients with SLE are actually less successful in attaining
federal disability assistance than patients with other dis-
eases because medical records may not accurately reflect
functional limitations, and SLE symptoms that contrib-
ute to work disability like fatigue, pain, and neurocogni-
tive dysfunction are difficult to assess and quantify [14].
In the current study, patients with SLE in the Medi-
care population were significantly more likely to use
healthcare resources than the matched control group
without SLE, and the higher rate of healthcare resource
utilization translated into significantly higher healthcare
costs. On average, patients in the SLE cohort had at least
two times more physician visits, hospitalizations, out-
patient visits, and emergency room visits when com-























































































n=6707 n=13,414 n=3348 n=6696













































































































n=936 n=1872 n=5771 n=11,542
Figure 4 Average Annual Healthcare Costs per Patient. ER = emergency room; MD = physician visit; OP = outpatient hospital visit; IP = inpatient
hospital stay; Other = other medical costs. *P < 0.0001 versus non-SLE group.
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per patient. The annual per-patient healthcare cost of
SLE in this study ($16,881 in 2008 USD) was similar to
or lower than the annual costs found in other studies of
a managed care or Medicaid population (approximately
$16,000-$30,000) [12,22-25]. While this study’s annual
health care cost figure does not include outpatient drug
costs given that outpatient drug costs are not includedin Medicare Part A or Part B datasets, previous studies
demonstrate that medication costs contribute a relatively
small proportion (6-23%) of direct healthcare costs for
SLE patients in studies of economic burden of SLE in
managed care [12,24,25].
The difference in healthcare costs between the SLE co-
hort and the non-SLE cohort was similar between the
matched sample as a whole and the subset of the
Garris et al. Cost Effectiveness and Resource Allocation  (2015) 13:9 Page 7 of 8matched sample on disability benefits. The difference in
costs between the SLE cohort and the non-SLE cohort
was also similar between males and females in the
matched sample as a whole but was magnified in blacks
compared with whites. Factors such as (a) greater disease
severity attributable to genetic and non-genetic (environ-
mental and socioeconomic) factors in blacks and other
minority groups [5,30] and (b) that severe flares of dis-
ease activity have been shown to incur higher costs [31]
may explain the latter finding, and warrants further
elucidation.
Inpatient costs were the primary drivers of the differ-
ence in healthcare costs between the SLE cohort and the
non-SLE cohort. Reasons for hospitalization among
these Medicare recipients with SLE were not determined
in this study. These reasons may be of interest, however,
as a study by Ward et al. [32] found that being on Medi-
care as opposed to having other types of health insur-
ance was a risk factor for avoidable hospitalization in
patients with SLE. Increasing age and lower socioeco-
nomic status were also associated with avoidable
hospitalization in the study. Ward suggested that as
Medicare can be obtained by patients receiving Social
Security Disability Insurance, Medicare might constitute
a marker for more severe illness than observed with
other types of healthcare insurance. The reasons for
hospitalization of patients with SLE merit systematic in-
vestigation in the context of the large contribution of
hospitalizations to the total medical cost of SLE.
One limitation to interpretation of study results is the
possible misidentification of Medicare beneficiaries with
SLE. The identification of SLE patients was based on
diagnosis codes where the potential for coding errors ex-
ists. The potential bias was minimized by requiring pa-
tients to have at least 2 separate medical claims with a
primary or secondary diagnosis of SLE. Second, prescrip-
tion medication data (i.e. Medicare Part D) was not
available for inclusion in the study, which would increase
the total economic burden of SLE. Third, clinical and
disease-specific parameters that could impact study out-
comes are not readily available in claims data. Despite
the lack of clinical parameters, claims data are very use-
ful in evaluating real-world resource utilization and cost
patterns.
Conclusions
This study quantifies the prevalence and economic bur-
den of SLE in a large Medicare population. The preva-
lence of SLE in this Medicare study sample (3 per 1,000
overall and 10 per 1,000 for disabled beneficiaries), was
higher than the national prevalence estimate of 1 per
1000 people. More than 40% of all SLE cases in the
Medicare sample (before matching) were patients <65
years of age receiving disability benefits. SLE isassociated with high healthcare resource utilization and
costs, on average 2 times higher utilization and $10,000
greater annual costs than non-SLE patients, with in-
patient hospitalization as the largest cost driver. Thus,
the Medicare population is an important patient seg-
ment to direct efforts to improve disease management
strategies and reduce costs of SLE.
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